Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Comparison Between FDG-positron Emission Tomography (FDG-PET)/Magnetic Resonance and FDG-PET/Computed Tomography for Staging, Interim Assessment and Restaging in Classical Hodgkin Lymhoma and DLBC Non-Hodgkin Lymphoma

NCT03042247 is registered in ClinicalTrials.gov with Marco Picardi as lead sponsor.

NCT NCT03042247
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03042247 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Comparison Between FDG-positron Emission Tomography (FDG-PET)/Magnetic Resonance and FDG-PET/Computed Tomography for Staging, Interim Assessment and Restaging in Classical Hodgkin Lymhoma and DLBC Non-Hodgkin Lymphoma
Lead sponsor
Marco Picardi
Phase
Observational
Overall status
Unknown status
Start date
January 24, 2017
Completion date
February 1, 2021
Enrollment
120 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

classical hodgkin lymphoma, diffuse large b-cell-lymphoma